Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.

Serena Williams reveals her use of GLP-1, Zepbound and calls out the stigma surrounding the use of the popular weight loss ...

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam ...

Serena Williams has revealed she lost 31 pounds on the GLP-1 Zepbound: "I just couldn't get my weight to where I needed to be at a healthy place." ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Serena Williams has a new doubles partner. The 23-time Grand Slam tennis champion is working with Ro, speaking out about how ...

The retired tennis pro explained that she’s trying to combat the stigma associated with weight loss drugs after losing 31 ...

GLP-1 drugs were also associated with a slight increase in risk for kidney cancer. The increase was not statistically ...

But what is important to me is transparency.” That calling has led her to this very moment: Williams is ready to share that ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

GLP-1 agonist users had a 17% lower cancer risk compared to non-users in a large retrospective study. The reductions achieved ...